Updated:
Viva Biotech (Shanghai) Ltd.
Established in 2008, Viva Biotech (01873.HK) provides one-stop services ranging from early-stage Structure-Based Drug R&D to commercial drug delivery to global...
Viva Biotech (Shanghai) Ltd.
Established in 2008, Viva Biotech (01873.HK) provides one-stop services ranging from early-stage Structure-Based Drug R&D to commercial drug delivery to global biopharmaceutical innovators. We offer l
General information
Firm type
Asset Manager
Year founded
2008
Location
Region
North America
Country
China
City
Shanghai
Corporate office
No.735, Ziping Road, Pudong New Area, Shanghai 201318, China
Additional offices
Bellevue, United States · Cambridge, United States
Sector focus
Frequently asked questions
Who runs investment decisions at Viva Biotech?
Viva Biotech is a publicly traded company (01873.HK) and its investment decisions for the EFS (equity-for-service) business are made by its management team. The firm does not publicly name a single CIO or investment head for the EFS portfolio. Corporate governance is overseen by a board of directors as disclosed in its Hong Kong Stock Exchange filings.
How does Viva Biotech source proprietary deal flow?
Viva's EFS model generates deal flow from its existing CRO client base. As clients engage Viva for drug discovery services, the firm identifies high-potential startups and offers service contracts in exchange for equity stakes. This creates a captive pipeline of companies that are already using Viva's platforms.
Does Viva Biotech participate in fund commitments or only direct deals?
Viva Biotech engages exclusively through direct equity stakes in portfolio companies via its EFS model. There is no public disclosure of any fund-of-funds or external GP commitment activity. The firm's investment activity is tied directly to its service relationships.
How is Viva Biotech related to Langhua Pharma?
Langhua Pharma is a wholly owned subsidiary of Viva Biotech that provides CMC (Chemistry, Manufacturing, and Control) services. It handles the manufacturing and commercial-scale production stage, extending Viva's one-stop offering from early discovery to commercial drug delivery.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: